SARS-CoV-2 antibody persistence after five and twelve months: A cohort study from South-Eastern Norway.

Autor: Sarjomaa M; Department of Infection Control, Telemark Hospital Trust, Skien, Norway.; Department of Community Medicine and Global Health and Society, University of Oslo, Oslo, Norway., Diep LM; Oslo Centre for Biostatistics and Epidemiology, Oslo, Norway., Zhang C; Oslo Centre for Biostatistics and Epidemiology, Oslo, Norway.; Norwegian Institute of Public Health, Oslo, Norway., Tveten Y; Department of Clinical Microbiology, Telemark Hospital Trust, Skien, Norway., Reiso H; The Norwegian National Advisory Unit on Tick-borne Diseases, Sørlandet Hospital Trust, Arendal, Norway., Thilesen C; Unilabs Laboratory Medicine, Skien, Norway., Nordbø SA; Department of Medical Microbiology, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway.; Norwegian University of Science and Technology, Trondheim, Norway., Berg KK; Department of Medical Microbiology, Sørlandet Hospital Trust, Kristiansand, Norway., Aaberge I; Norwegian Institute of Public Health, Oslo, Norway., Pearce N; London School of Hygiene and Tropical Medicine, London, United Kingdom., Kersten H; Department of Research, Telemark Hospital Trust, Skien, Norway.; School of Pharmacy, University of Oslo, Oslo, Norway., Vandenbroucke JP; London School of Hygiene and Tropical Medicine, London, United Kingdom.; University of Leiden, Leiden, Netherlands.; University of Aarhus, Aarhus, Denmark., Eikeland R; Department of Health and Nursing Science, University of Agder, Grimstad, Norway.; Department of Occupational and Environmental Medicine, Telemark Hospital Trust, Skien, Norway., Fell AKM; Department of Community Medicine and Global Health and Society, University of Oslo, Oslo, Norway.; Department of Occupational and Environmental Medicine, Telemark Hospital Trust, Skien, Norway.
Jazyk: angličtina
Zdroj: PloS one [PLoS One] 2022 Aug 10; Vol. 17 (8), pp. e0264667. Date of Electronic Publication: 2022 Aug 10 (Print Publication: 2022).
DOI: 10.1371/journal.pone.0264667
Abstrakt: Objectives: To assess total antibody levels against Severe Acute Respiratory Syndrome CoronaVirus 2 (SARS CoV-2) spike protein up to 12 months after Coronavirus Disease (COVID-19) infection in non-vaccinated individuals and the possible predictors of antibody persistence.
Methods: This is the first part of a prospective multi-centre cohort study.
Participants: The study included SARS-CoV-2 real-time polymerase chain reaction (RT-PCR) positive and negative participants in South-Eastern Norway from February to December 2020. Possible predictors of SARS-CoV-2 total antibody persistence was assessed. The SARS-CoV-2 total antibody levels against spike protein were measured three to five months after PCR in 391 PCR-positive and 703 PCR-negative participants; 212 PCR-positive participants were included in follow-up measurements at 10 to 12 months. The participants completed a questionnaire including information about symptoms, comorbidities, allergies, body mass index (BMI), and hospitalisation.
Primary Outcome: The SARS-CoV-2 total antibody levels against spike protein three to five and 10 to 12 months after PCR positive tests.
Results: SARS-CoV-2 total antibodies against spike protein were present in 366 (94%) non-vaccinated PCR-positive participants after three to five months, compared with nine (1%) PCR-negative participants. After 10 to 12 months, antibodies were present in 204 (96%) non-vaccinated PCR-positive participants. Of the PCR-positive participants, 369 (94%) were not hospitalised. The mean age of the PCR-positive participants was 48 years (SD 15, range 20-85) and 50% of them were male. BMI ≥ 25 kg/m2 was positively associated with decreased antibody levels (OR 2.34, 95% CI 1.06 to 5.42). Participants with higher age and self-reported initial fever with chills or sweating were less likely to have decreased antibody levels (age: OR 0.97, 95% CI 0.94 to 0.99; fever: OR 0.33, 95% CI 0.13 to 0.75).
Conclusion: Our results indicate that the level of SARS-CoV-2 total antibodies against spike protein persists for the vast majority of non-vaccinated PCR-positive persons at least 10 to 12 months after mild COVID-19.
Competing Interests: The authors have declared that no competing interests exist.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje